ClinicalTrials.gg
CompletedNCT02732522CMVSUpdated Apr 8, 2016

Comparison Between Vaginal and Sublingual Misoprostol 50 µg for Cervical Ripening Prior to Induction of Labor

A Phase 4 interventional study of Sublingual misoprostol and Vaginal misoprostol in Cervical Ripening, sponsored by Universidad de la Republica. Completed. Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-08.

Sponsored by Universidad de la Republica · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
102
Allocation
Randomized
Sex
Female
01

Study summary

To analyze whether there is a statistically significant difference in the modifications present in the uterine cervix 6 hours after administration of misoprostol 50 µg through vaginal versus sublingual routes.

Read the detailed description

A randomized, single blind clinical trial, was performed. Inclusion criteria were all pregnant women admitted at Pereira Rossell Hospital Center with gestational ages between 32/0 and 41/6 according to first trimester sonogram, with a viable fetus in cephalic presentation, with estimated fetal weight lower than 4000 gr, without contraindications for vaginal birth, to whom induction of labor with misoprostol had been previously indicated, from 8 to 20 hours 7 days a week. Protocol counted with approval of the Ethics Commission of the Pereira Rossell Hospital. All participants gave written informed consent before the study began. Once there was confirmation that the patient met the inclusion criteria, information was given and consent form was signed, the patient entered the study and the intervention was randomized. Randomization was computer generated in permuted blocks of 2 by an epidemiologist from our Service, and the result was in a sealed and opaque envelope which was opened at the time of administering the medication. Prior to administration of the medication, an Obstetrician or Obstetrics resident who was not familiar with the administration route assigned to the patient assessed through vaginal examination the characteristics of the cervix in terms of Bishop score. Afterwards, a technician from the investigation team administered the misoprostol according to the assigned route (50 µg misoprostol vaginal or sublingual).

Tachysystole was defined as the presence of at least 6 uterine contractions in 10 minutes.

Primary result was defined as the clinically significant variation (of at least 2 points) of the Bishop score at 6 hours after administration of 50 µg misoprostol. Secondary results were defined as the presence of tachysystole, frequency of vaginal birth and cesarean section, frequency in which new doses were needed to continue with induction of labor and frequency with which labor was diagnosed at 6 hours of administration of misoprostol. Neonatal results included Apgar score at 1 and 5 minutes and pH value in umbilical cord gasometry. Final analysis was made according to intention to treat.

In order to detect a difference in the mean of Bishop score of 2 points, using a standard deviation of 2, with a 90% power, reaching a confidence interval of 95%, a population of 49 patients was required for each group.

Randomization was done in permuted blocks of 2, using a table of randomized numbers. Group 1 included those patients who received sublingual misoprostol and group 2 those patients who received vaginal misoprostol. Analysis was done in statistical package SPSS (reg) V16. For continuous variables a mean and standard deviation were described; for categorical variables absolute frequency and percentage were described. For statistical analysis a 2-tiled independent t-test was used, in order to compare the mean of the two groups. Also, chi-squared test and Fisher´s exact test were used to compare proportions among the two groups where it corresponds.

02

Conditions studied

  • Cervical Ripening

Keywords

  • misoprostol
  • induction of labor
  • sublingual
03

In context

Lead sponsor

Universidad de la Republica is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All pregnant women admitted at Pereira Rossell Hospital Center
  • Gestational ages between 32/0 and 41/6 according to first trimester sonogram
  • A viable fetus in cephalic presentation
  • Estimated fetal weight lower than 4000 gr
  • Without for vaginal birth
  • Whom induction of labor with misoprostol had been previously indicated, from 8 to 20 hours 7 days a week.

Exclusion criteria

Exclusion Criteria:

  • Does not meet inclusion criteria.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Misoprostol sublingual

    Drug: Sublingual misoprostol

  • Active comparator
    Misoprostol vaginal

    Drug: Vaginal misoprostol

06

What researchers measure

Primary outcomes

  1. Bishop score at 6 hours after administration of misoprostol

    Time frame: 6 hours

Secondary outcomes

  1. Number of participants with Tachysystole

    Tachysystole was defined as the presence of at least 6 uterine contractions in 10 minutes.

    Time frame: 6 hours

  2. Number of patients who ended their pregnancy by caesarean section

    Time frame: From administration of misoprostol to birth, up to 3 days.

  3. Requirement of further doses of misoprostol

    Time frame: From administration of misoprostol to birth, up to 3 days.

  4. Labor within 6 hours

    Time frame: 6 hours

  5. Apgar score at 1 minute

    Time frame: At the first minute after delivery

  6. Apgar score at 5 minutes

    Time frame: At the fifth minute after delivery

  7. pH cord blood gas

    Time frame: At delivery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Conde A, Ben S, Tarigo J, Artucio S, Varela V, Grimaldi P, Sosa C, Alonso J. Comparison between vaginal and sublingual misoprostol 50 microg for cervical ripening prior to induction of labor: randomized clinical trial. Arch Gynecol Obstet. 2017 Apr;295(4):839-844. doi: 10.1007/s00404-017-4297-9. Epub 2017 Feb 16. PubMed 28204882 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02732522
Lead sponsor
Universidad de la Republica
Responsible party
Andrés Conde (M.D., Universidad de la Republica) — Principal investigator
First posted
Apr 8, 2016
Start date
Oct 2014
Primary completion
May 2015
Completion
Jan 2016
Last update
Apr 8, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Misoprostol

Start the discussion